Scott Peter Seidelmann Sells 3,765 Shares of Omnicell, Inc. (NASDAQ:OMCL) Stock

Omnicell, Inc. (NASDAQ:OMCLGet Rating) EVP Scott Peter Seidelmann sold 3,765 shares of Omnicell stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $110.15, for a total value of $414,714.75. Following the transaction, the executive vice president now directly owns 40,789 shares in the company, valued at $4,492,908.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OMCL traded down $2.88 during trading on Friday, reaching $107.07. The company had a trading volume of 808,605 shares, compared to its average volume of 432,854. The firm’s 50-day simple moving average is $113.41 and its 200 day simple moving average is $138.45. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 71.86, a PEG ratio of 2.07 and a beta of 1.21. Omnicell, Inc. has a 12-month low of $104.32 and a 12-month high of $187.29.

Omnicell (NASDAQ:OMCLGet Rating) last released its earnings results on Thursday, April 28th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.13. Omnicell had a return on equity of 11.35% and a net margin of 6.00%. The company had revenue of $319.00 million for the quarter, compared to analysts’ expectations of $313.98 million. During the same quarter in the previous year, the business posted $0.62 EPS. The business’s revenue for the quarter was up 26.7% on a year-over-year basis. Analysts anticipate that Omnicell, Inc. will post 2.73 earnings per share for the current fiscal year.

OMCL has been the topic of a number of research analyst reports. Wells Fargo & Company lowered their target price on Omnicell from $188.00 to $158.00 and set an “overweight” rating on the stock in a report on Tuesday, May 3rd. TheStreet lowered Omnicell from a “b-” rating to a “c+” rating in a report on Tuesday, May 17th. StockNews.com assumed coverage on Omnicell in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Piper Sandler dropped their price target on Omnicell from $181.00 to $162.00 in a research note on Monday, May 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $186.25.

Large investors have recently added to or reduced their stakes in the business. Sageworth Trust Co of South Dakota purchased a new position in Omnicell during the 4th quarter valued at about $27,000. Covestor Ltd purchased a new position in Omnicell during the 4th quarter valued at about $29,000. Spire Wealth Management purchased a new position in Omnicell during the 1st quarter valued at about $25,000. Liberty Wealth Management LLC grew its stake in Omnicell by 47.7% during the 3rd quarter. Liberty Wealth Management LLC now owns 195 shares of the company’s stock valued at $32,000 after acquiring an additional 63 shares in the last quarter. Finally, Elequin Capital LP acquired a new stake in shares of Omnicell during the 1st quarter valued at about $30,000.

About Omnicell (Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Stories

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Want More Great Investing Ideas?

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.